Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RL1 null mutant vector – potential glioblastoma targeting (original) (raw)

Gene Therapy volume 5, pages 440–450 (1998)Cite this article

Abstract

Due to the lack of any effective therapy, novel approaches are currently being explored for the treatment of primary brain tumours. It has previously been demonstrated that variants of HSV-1 which are deleted in the RL1 gene and fail to produce the virulence factor ICP34.5 are potential candidates for tumour therapy. The RL1 variant 1716 replicates selectively within tumour cells and has the potential to deliver a therapeutic or tumour killing gene directly to the site of tumour growth. As many intracerebral tumours are glial and predominantly astrocytic in origin, we have evaluated the ability of 1716 to deliver a reporter gene specifically to astrocytes in vivo and in vitro using a 2.2 kb fragment which controls expression of the glial fibrillary acidic protein (GFAP), an astrocyte specific protein. Two 1716 variants, 1774 and 1775, were constructed which contain the GFAP-promoter element linked to the E. coli β-galactosidase gene, inserted into the HSV-1 UL43 and US5 loci, respectively. In primary cultures, human primary tumour cell lines and established tumour cell lines in vitro, 1774 and 1775 gave high levels of expression of β- galactosidase specifically in astrocytes. In vivo following intracerebral inoculation, both viruses demonstrated high levels of β-galactosidase expression predominantly in astrocytes. These results indicate that the GFAP promoter element could be used for efficient and selective transgene delivery to human gliomas.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 6 print issues and online access

$259.00 per year

only $43.17 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Glasgow University Neurovirology Research Laboratories, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
    EA McKie & SM Brown
  2. Department of Neuropathology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
    DI Graham

Authors

  1. EA McKie
    You can also search for this author inPubMed Google Scholar
  2. DI Graham
    You can also search for this author inPubMed Google Scholar
  3. SM Brown
    You can also search for this author inPubMed Google Scholar

Rights and permissions

About this article

Cite this article

McKie, E., Graham, D. & Brown, S. Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RL1 null mutant vector – potential glioblastoma targeting.Gene Ther 5, 440–450 (1998). https://doi.org/10.1038/sj.gt.3300621

Download citation

Keywords